Trial Profile
Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy With Erythropoietin: A Phase III Randomised Placebo Controlled Multicentre Clinical Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Cerebral ischaemia; Encephalopathy
- Focus Adverse reactions
- Acronyms PAEAN
- 17 Sep 2021 Planned End Date changed from 1 Mar 2023 to 31 Mar 2023.
- 26 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Mar 2023.
- 26 Apr 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2023.